Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 11/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392252 | 0.92 | TNIK (0.60) | TNIKKDM4EL3MBTL1KDR | |
| SCHEMBL3394890 | 0.92 | TNIK (0.59) | TNIKKDM4EL3MBTL1KDR | |
| SCHEMBL3390733 | 0.91 | TNIK (0.62) | TNIKL3MBTL1KDR | |
| SCHEMBL3398691 | 0.88 | TNIK (0.64) | TNIK | |
| SCHEMBL3394602 | 0.88 | TNIK (0.60) | TNIKKDM4EALDH1A1HIF1AEPAS1 | |
| SCHEMBL3394625 | 0.87 | TNIK (0.63) | TNIKALDH1A1KMT2A | |
| SCHEMBL13333372 | 0.86 | TNIK (0.49) | TNIKKDM4EALDH1A1KDRKMT2A | |
| SCHEMBL3393893 | 0.84 | TNIK (0.67) | TNIK | |
| SCHEMBL3398128 | 0.84 | TNIK (0.77) | TNIKKMT2A | |
| SCHEMBL2367263 | 0.83 | TNIK (0.66) | TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364149-B1 | TNIK INHIBITOR AND THE USE | NAT CANCER CT (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-06-03 | — | — | US | disclosed |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-06-03 | — | — | US | disclosed |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | TNIK 1/4885KDM4E 918/4885ALDH1A1 3970/4885 |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | TNIK 1/4885KDM4E 946/4885ALDH1A1 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.